{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000039","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.894772+00:00","generated_at":"2026-06-15T05:36:37.413932+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspira Women's Health Q1 revenue up 26% to $2.3M; OvaSuite volume +29%","bullets":["Product revenue $2.3M (+26% YoY); OvaSuite volume 6,259 units (+29% YoY).","Cash used in operations $5.7M, down 44% from $10.2M YoY; total cash $7.5M at Mar 31.","Gross margin 51.4% vs 50.8%; revenue per test $370 (-2%).","2H 2023 milestones: OvaWatch serial monitoring test study completion, EndoCheck launch.","Board approved 1-for-15 reverse stock split; secured up to $22.5M in capital facilities."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000039","json":"https://secwatch.observer/filing/0000926617-23-000039.json","markdown":"https://secwatch.observer/filing/0000926617-23-000039.md","text":"https://secwatch.observer/filing/0000926617-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/0000926617-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/awh-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:36:37.413932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b295b1ef2c4af7a716a3015de1c005a19c7fb284","claim":"Aspira Women's Health Inc. reported the three months ended March 31, 2023 results: revenue $2.3 million. Guidance reaffirmed.","evidence_excerpt":"regardless of any incorporation by reference language in such filing.  --- EX-99.1 (EX-99.1) --- 2023-05-11 8K Ex 991 Exhibit 99 .1 First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year  First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year  First Quarter cash used in operations of $5.7 million, a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/0000926617-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$2.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}